Talquetamab, a GPRC5DXCD3 Bispecific Antibody, for Treatment of Relapsed/Refractory Multiple Myeloma in Patients With Prior Exposure to BCMA Targeted Therapies - a "Real World" Study

被引：0
|
作者：
Shkury, Eden [1 ]
Hellou, Tamer [2 ]
Nevo, Lee [2 ]
Avigdor, Abraham [2 ]
Magen, Hila [2 ]
机构：
[1] Sheba Tel HaShomer Med Ctr, Tel Hashomer, Israel
[2] Tel Aviv Univ, Chaim Sheba Med Ctr, Fac Med & Hlth Sci, Tel Aviv, Israel
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-081
引用
收藏
页码：S88 / S89
页数：2
相关论文
共 50 条
  • [41] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
    Laheij, A. M. G. A.
    van de Donk, N. W. C. J.
    SUPPORTIVE CARE IN CANCER, 2024, 32 (01)
  • [42] BCMA after GPRC5D: Efficacy of BCMA-Directed Therapy on Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Progressing After GPRC5D-Directed Therapy
    Joiner, Laura
    Costa, Luciano
    Giri, Smith
    Ravi, Gayathri
    Godby, Kelly
    Hagedorn, Caitlin
    Bal, Susan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S61 - S62
  • [43] First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Cohen, Yael C.
    Morillo, Daniel
    Gatt, Moshe E.
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Oriol, Albert
    Ocio, Enrique M.
    Yoon, Sung-Soo
    Mateos, Maria-Victoria
    Chu, Michael
    Rodriguez-Otero, Paula
    Avivi, Irit
    Guo, Yue
    Krevvata, Maria
    Peterson, Michelle R.
    Beelen, Melissa Jo
    Vanak, Jill
    Banerjee, Arnob
    Magen, Hila
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma
    Costa, Bruno Almeida
    Tan, Carlyn Rose
    Shekarkhand, Tala
    Firestone, Ross S.
    Jurgens, Eric M.
    Miller, Kevin
    Lesokhin, Alexander M.
    Shah, Gunjan L.
    Korde, Neha
    Rajeeve, Sridevi
    Chung, David J.
    Landau, Heather J.
    Scordo, Michael
    Hassoun, Hani
    Maclachlan, Kylee H.
    Shah, Urvi A.
    Hultcrantz, Malin
    Hamadeh, Issam S.
    Giralt, Sergio
    Mailankody, Sham
    Usmani, Saad Z.
    Hashmi, Hamza
    BLOOD, 2024, 144 : 7026 - 7027
  • [45] First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Magen, Hila
    Morillo, Daniel
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Oriol, Albert
    Ocio, Enrique
    Yoon, Sung-Soo
    Mateos, Maria-Victoria
    Chu, Michael
    Rodriguez-Otero, Paula
    Avivi, Irit
    Guo, Yue
    Krevvata, Maria
    Peterson, Michelle
    Beelen, Melissa
    Vanak, Jill
    Banerjee, Arnob
    Cohen, Yael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S49 - S50
  • [46] Taste Abnormalities Emerging during Anti- Myeloma Therapies Including GPRC5D x CD3 Bispecific Antibody Talquetamab
    Fleischer, Anna
    Roll, Magdalena
    Panther, Franziska
    Gelbrich, Goetz
    Reinhardt, Franziska
    Riedhammer, Christine
    Mersi, Julia
    Waldschmidt, Johannes M.
    Einsele, Hermann
    Kortuem, K. Martin
    Maatouk, Imad
    Rasche, Leo
    BLOOD, 2023, 142
  • [47] Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1+1 greater than 2?
    Li, Chenggong
    Mei, Heng
    LANCET HAEMATOLOGY, 2024, 11 (10): : e712 - e713
  • [48] Lbl-034, a Highly Differentiated T-Cell Engaging Bispecific Antibody Targeting GPRC5D for the Treatment of Relapsed or Refractory Multiple Myeloma
    Wang, Baohui
    Huang, Xiao
    Sun, Jianming
    Qin, Yurong
    Shang, Hongyan
    Li, Tingting
    Wu, Guojin
    Chen, Min
    Wang, Hailin
    Zhang, Peng
    Jiang, Duqing
    Liu, Tongjun
    Ye, Mi
    Cai, Shengli
    Lai, Shoupeng
    Kang, Xiaoqiang
    Ling, Hong
    BLOOD, 2023, 142
  • [49] Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers
    Schinke, Carolina
    Dhakal, Binod
    Mazzoni, Sandra
    Shenoy, Samantha
    Scott, Sara A.
    Richards, Tiffany
    Le, Hoa H.
    DeBrosse, Amalia
    Okorozo, Peter
    McDowell, Rachel
    Patel, Saurabh
    Bunn, Jonathan
    Hawks, Kelly
    Zhang, Xinke
    Rodriguez, Cesar
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (10) : 1705 - 1711
  • [50] A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Berdeja, Jesus G.
    Oriol, Albert
    van de Donk, Niels W. C. J.
    Rodriguez, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Minnema, Monique C.
    Verona, Raluca
    Girgis, Suzette
    Prior, Thomas
    Hilder, Brandi W.
    Russell, Jeffery
    Goldberg, Jenna D.
    Krishnan, Amrita
    BLOOD, 2020, 136
12345